Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

NCT06365970 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Per drug sponsor request.

Conditions

MMR-D/MSI-H Colorectal Cancers

Interventions

DRUG: Niraparib
DRUG: Dostarlimab

Sponsor

Ibrahim Halil Sahin

Collaborators

[object Object]